NASDAQ:HITK - Hi-Tech Pharmacal Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Hi-Tech Pharmacal Co., Inc. is a specialty manufacturer and marketer of prescription, over-the-counter and nutritional products. The Company develops, manufactures and markets products in three categories: generics, prescription brands and over-the-counter (OTC) brands. It produces a range of products for various disease states, including glaucoma, asthma, bronchial disorders, dermatological disorders, allergies, pain, stomach, oral care and other conditions. The Company's generic products are primarily prescription items and include oral solutions and suspensions, topical creams and ointments as well as nasal sprays. It also specializes in the manufacture of products in its sterile facility capable of producing liquid ophthalmic, otic and inhalation products. In April 2014, Akorn Inc acquired Hi-Tech Pharmacal Co., Inc.

Receive HITK News and Ratings via Email

Sign-up to receive the latest news and ratings for HITK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
Current SymbolNASDAQ:HITK
CUSIP42840B10
Phone+1-516-7898228

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Hi-Tech Pharmacal (NASDAQ:HITK) Frequently Asked Questions

What is Hi-Tech Pharmacal's stock symbol?

Hi-Tech Pharmacal trades on the NASDAQ under the ticker symbol "HITK."

Has Hi-Tech Pharmacal been receiving favorable news coverage?

Headlines about HITK stock have been trending somewhat negative this week, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Hi-Tech Pharmacal earned a news sentiment score of -1.4 on InfoTrie's scale. They also gave news headlines about the healthcare company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next several days.

What other stocks do shareholders of Hi-Tech Pharmacal own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hi-Tech Pharmacal investors own include KINGFISHER PLC/SH (KGFHY), Ensco (ESV), Whiting Canadian (KOG), The GEO Group (GEO), STRATA Skin Sciences (SSKN), Hercules Offshore Com (HEROQ), KeyCorp (KEY), Hi-Crush Partners (HCLP), Barracuda Networks (CUDA) and Brown-Forman (BF.A).

How do I buy shares of Hi-Tech Pharmacal?

Shares of HITK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Hi-Tech Pharmacal's official website?

The official website for Hi-Tech Pharmacal is http://www.hitechpharm.com.

How can I contact Hi-Tech Pharmacal?

Hi-Tech Pharmacal's mailing address is 369 Bayview Ave, AMITYVILLE, NY 11701-2801, United States. The healthcare company can be reached via phone at +1-516-7898228.


MarketBeat Community Rating for Hi-Tech Pharmacal (NASDAQ HITK)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  83 (Vote Outperform)
Underperform Votes:  71 (Vote Underperform)
Total Votes:  154
MarketBeat's community ratings are surveys of what our community members think about Hi-Tech Pharmacal and other stocks. Vote "Outperform" if you believe HITK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HITK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/26/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel